Celltrion presents strategic vision and growth plan

15 January 2024

South Korea’s Celltrion (Kosdaq: 068270) has announced the next phase of its strategic transformation from a developer of the world's first monoclonal antibody (Mab) biosimilar to an innovative company focused on new drug development at the 42nd Annual JP Morgan Healthcare Conference in San Francisco, California.

Chairman and chief executive Jin-Seok Seo highlighted Celltrion's solid business results from the approval of the world's first monoclonal antibody biosimilar Remsima (infliximab), branded Inflectra in the USA, to the successful transition to a direct sales model. Remsima/Inflectra is marketed by Johnson & Johnson (NYSE: JNJ) subsidiary Janssen.

He also shared insights and trends on the biosimilar industry and how the market landscape is impacting Celltrion's strategy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK